Product Description
Mechanisms of Action: Tubulin Inhibitor
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Chile | China | India
Approved Indications: None
Known Adverse Events: None
Company: Shanghai tenth People's Hospital
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Thyroid Cancer
Phase 1: Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
SCRC21021CTIL | N/A |
Recruiting |
Thyroid Cancer|Lymphatic Metastasis |
2024-12-31 |
|
ChiCTR2000036620 | N/A |
Not yet recruiting |
Thyroid Cancer |
2023-12-31 |
|
ChiCTR2200055183 | N/A |
Recruiting |
Thyroid Cancer |
2023-01-30 |
|
NCI-2015-01781 | P1 |
Terminated |
Oncology Solid Tumor Unspecified|Oncology Hematological Unspecified |
2020-07-01 |